Bio-Rad purchases AbD Serotec for €53m

Adds more than 15,000 antibodies, kits and accessories to life science products

Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products, has bought AbD Serotec, a division of MorphoSys, for approximately €53m in cash.

AbD Serotec offers more than 15,000 antibodies, kits, and accessories. The company has an ISO 9001 and ISO 13485 certified production facility in Kidlington, near Oxford in the UK, as well as other facilities in Düsseldorf, Germany and Raleigh, NC in the US.

‘We are pleased to have AbD Serotec join Bio-Rad,’ said Norman Schwartz, Bio-Rad’s president and CEO. ‘With AbD Serotec’s comprehensive catalogue of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting.’

Founded in 1952, Bio-Rad is headquartered in Hercules, California, US and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs more than 7,100 people globally and had revenues exceeding US$2bn in 2011.

Companies